FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2741-2744 June 19, 2008 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schwarz, U. I.

To the Editor: In the study reported by Schwarz et al. (March 6 issue),¹ specific genetic variants related to warfarin metabolism reduced the time to the first therapeutic and supratherapeutic international normalized ratio (INR) tests. A pharmacogenetic-guided dosing algorithm for warfarin,² however, did not increase the time in the therapeutic range or reduce the proportion of supratherapeutic INR values. An exploratory analysis suggested that the algorithm may be useful for genetic subtypes. Although scientific discourse about personalized medicine has focused on pharmacogenomics, this view limits the extent to which discovery can improve the public's health. My research group has shown . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.